Compounded tirzepatide and the Ivím weight loss program
A weekly GLP-1 injection to lose weight, curb hunger, and regulate blood sugar.*
FDA notice on Zepbound™/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim provider to discuss what this means for you and your treatment options.
*While federal law allows the prescription of compounded drugs, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review. For additional safety information, please see our Safety Page.
*Disclaimer: Mounjaro® and Zepbound™ are both registered trademarks of Eli Lilly. Ivím is not affiliated with Eli Lilly.
Real members,
real
results*
*Personal results may vary based on our individualized health programs.